Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Psoriatic arthritis (PsoA)

Pooled analysis on the efficacy of secukinumab from four phase III studies

    • Dermatology and venereology
    • Education
    • General Internal Medicine
    • Rheumatology
    • RX
    • Studies
  • 3 minute read

Improvement in clinical endpoints was seen with secukinumab treatment regardless of latency since initial psoriatic arthritis diagnosis, with patients diagnosed less than one year ago showing a slightly better response than those diagnosed more than two years ago. In another post-hoc analysis of a data pool of the same four studies, the efficacy of secukinumab as first-line therapy was shown to be superior compared to patients pretreated with anti-TNFα.

Psoriatic arthritis (PsoA) can progress rapidly if left untreated, leading to irreversible damage within two years of initial diagnosis [1]. The selective interleukin (IL)-17 inhibitor secukinumab showed rapid and sustained symptom improvement in the phase III FUTURE 1-5 trials. The median duration since PsoA diagnosis in these studies was 6-7 years [2–6]. To gain a better understanding regarding the effects of prior therapeutic intervention in patients with PsoA, an evaluation of secukinumab treatment as a function of duration since initial PsoA diagnosis was performed [7]. To this end, pooled data (n=1803) from the FUTURE 2-5 randomized-controlled trials were analyzed*. Included patients received either secukinumab (s.c.) 300 mg or 150 mg as loading dose, secukinumab 150 mg without loading dose, or placebo. The patients were divided into two groups: group 1 included patients who had been diagnosed with PsoA ≤1 year ago, and group 2 included patients who had been diagnosed with PsoA >2 years ago. Treatment response was assessed by, among other things, changes in ACR20/50/70 as well as PASI75/90/100 after 16 weeks**. Quality of life and disease activity outcome parameters were also recorded.

* FUTURE 2 (NCT01752634), FUTURE 3 (NCT01989468), FUTURE 4 (NCT02294227) and 5 (NCT02404350).
** Non-Responder Imputation; no correction regarding multiple comparisons.

Higher symptom improvement with lower treatment latency.

Overall, 419 patients (23.2%) had a first PsoA diagnosis ≤1 year ago at the start of treatment with secukinumab, and 1384 (76.8%) had a treatment latency >of 2 years [7]. At baseline, most relevant patient characteristics of these two groups were comparable. At week 16, ACR20/50/70 response rates proved higher with secukinumab treatment compared with placebo, regardless of latency in time since PsoA diagnosis (Fig. 1), with secukinumab 300 mg associated with higher ACR response rates than secukinumab 150 mg. In general, ACR response rates were slightly higher in patients with a treatment latency ≤1 year, particularly in those receiving secukinumab 300 mg. Secukinumab also proved superior to placebo in terms of other outcome parameters such as enthesitis, dactylitis, skin psoriasis and nail psorisais. A higher proportion of patients with a secukinumab treatment latency ≤1 year compared with the group with an >initial PsoA diagnosis 2 years earlier had no swollen joints and no tender joints at all (“swollen joint count” = 0, “mean tender joint count” = 0) and a CRP ≤10 mg/L. Patients with lower treatment latency also performed better on subscores for psychological well-being in the SF-36 (“Short Form-36 of the Health Survey”). The most common adverse events in patients treated with secukinumab (time since diagnosis ≤1 year and  >2 years, respectively) were nasopharyngitis (8.3% and 6.1%, respectively), headache (6.2% and 3.6%, respectively), and upper respiratory tract infections (5.1% and 4.7%, respectively).

 

 

Data on secukinumab as first-line treatment

First, a further post-hoc analysis of pooled data (n=2049) from the FUTURE 2-5 trials showed that the efficacy of secukinumab was superior to placebo in all of the domains of clinical PsoA manifestation defined by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) (peripheral arthritis, axial involvement, enthesitis, dactylitis, skin psoriasis, nail involvement) [8]. Second, the clinical response was higher in anti-TNFα-naive patients compared to those previously treated with TNFα inhibitors. These results provide an argument for using secukinumab as a first-line treatment option.

 

Literature:

  1. Kane D, et al: Rheumatology (Oxford) 2003; 42: 1460-1468.
  2. Mease PJ, et al. RMD Open 2018; 4: e000723.
  3. McInnes IB, et al. Lancet 2015; 386: 1137-1146.
  4. Nash P, et al. Arthritis Res Ther 2018; 20: 47.
  5. Kivitz A, et al. Rheumatol Ther 2019; 6(3): 393-407.
  6. Mease PJ, et al. Ann Rheum Dis 2018; 77: 890-897.
  7. Ritchlin C, et al: Arthritis Rheumatol 2020; 72 (suppl 10). https://acrabstracts.org/abstract/efficacy-of-secukinumab-treatment-in-patients-with-early-psoriatic-arthritis-a-pooled-analysis-of-4-phase-3-studies (last accessed Sep 20, 2021).
  8. Orbai AM, et al: Rheumatol Ther 2021: 1223-1240.

 

DERMATOLOGIE PRAXIS 2021; 31(5): 57-58

Autoren
  • Mirjam Peter, M.Sc.
Publikation
  • DERMATOLOGIE PRAXIS
Related Topics
  • psoa
  • Psoriatic Arthritis
Previous Article
  • From symptom to diagnosis

Joint diagnostics: plantar pain – Ledderhose disease

  • Cases
  • Education
  • General Internal Medicine
  • Orthopedics
  • Radiology
  • RX
View Post
Next Article
  • Primary hyperaldosteronism

Therapy-resistant hypertension: clarify for Conn syndrome!

  • Cardiology
  • Education
  • Endocrinology and Diabetology
  • General Internal Medicine
  • RX
  • Studies
View Post
You May Also Like
View Post
  • 6 min
  • Interview with Prof. Thomas Kündig (USZ)

“If we control itching and eczema, a normal life is possible again”

    • Dermatology and venereology
    • Interviews
    • Partner Content
    • RX
View Post
  • 3 min
  • From symptom to diagnosis

Abdominal pain – groin pain: internal causes

    • Cases
    • Education
    • Gynecology
    • Radiology
    • RX
    • Surgery
    • Urology
View Post
  • 2 min
  • Chronic pain

Nano-ECS modulator Adezunap improves therapy success

    • Congress Reports
    • General Internal Medicine
    • Pharmaceutical medicine
    • Pharmacology and toxicology
    • Phytotherapy
    • Rheumatology
    • RX
    • Studies
View Post
  • 8 min
  • Psoriasis and PsA

Biologics, oral peptide and trivalent nanobody – current results and trends

    • Allergology and clinical immunology
    • Congress Reports
    • Dermatology and venereology
    • Rheumatology
    • RX
    • Studies
View Post
  • 5 min
  • Cancer in Europe: facts and analysis

New Health Policy Report published

    • General Internal Medicine
    • Oncology
    • Practice Management
    • Prevention and health care
    • RX
    • Studies
View Post
  • 4 min
  • Gastrointestinal complaints

PPI regulation under the microscope

    • Education
    • Gastroenterology and Hepatology
    • General Internal Medicine
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 6 min
  • Wound management: clinical diagnostics

Assessing the risk of infection – from the ABCDE to the TILI score

    • Congress Reports
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Geriatrics
    • Infectiology
    • Interviews
    • Physical medicine and rehabilitation
    • Prevention and health care
    • RX
View Post
  • 4 min
  • Study report

Digital patient education for atrial fibrillation shows measurable effects

    • Cardiology
    • Education
    • General Internal Medicine
    • RX
    • Studies
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
Top CME content
  • 1
    How combination therapies lead to better treatment results
  • 2
    Interplay between cancer and mental illness
  • 3
    PH and lung diseases
  • 4
    Treatment of comorbidities in older people
  • 5
    Multidisciplinary teams in oncology

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.